Figure 3.

Panitumumab reverses FTD‐induced ERK1/2 and AKT phosphorylation and EGFR gel mobility shift in LIM1215 cells. LIM1215 cells were seeded onto a six‐well plate and cultured for 24 h. The cells were subsequently treated with FTD (3 μm), panitumumab (100 ng·mL ⁻¹), erlotinib (10 μm), or a combination of FTD and panitumumab for 24 h, followed by western blotting analyses. FTD‐induced band mobility shift of EGFR is indicated as ‘shifted’ versus ‘basal’. GAPDH was used as a loading control. The blots are representative of two independent experiments.